Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively.